Skip to Content

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

This year’s ESMO congress will present new late-breaking data for doublet immune therapy for patients with localized renal cell carcinoma. This may give hope to extending the time patients live without recurrence.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top